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Abstract 
Pancreas transplantation has emerged as an effective treatment for patients with diabetes mellitus, especially 
those with established end-stage renal disease. Surgical and immunosuppressive advances have significantly 
improved allograft survival. The procedure reduces mortality compared with diabetic kidney transplant 
recipients and waitlisted patients. Improvements in diabetic nephropathy and retinopathy have also been 
demonstrated. Pancreas transplantation can improve cardiovascular risk profiles, improve cardiac function, and 
decrease cardiovascular events. Finally, improvements in diabetic neuropathy and quality of life can result 
from pancreas transplantation. Pancreas transplantation remains the most effective method to establish durable 
euglycemia for patients with diabetes mellitus. 
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Introduction 
Diabetes mellitus afflicts about 6% of the general 
population; it is currently the third most common 
disease and the fourth leading cause of death by disease 
in the United States. Of the estimated 21 million 
diabetic individuals in the United States, 1-2 million 
has insulin-dependent diabetes mellitus (IDDM). 
Nearly 300,000 new cases of IDDM are diagnosed 
each year, and the incidence is increasing (1). Pancreas 
transplantation has assumed an increasingly important 
role in the treatment of IDDM. It is currently the only 
available treatment that reliably provides an insulin-
independent state, resulting in euglycemia and normal 
glycosylated hemoglobin levels by re-establishing 
endogenous insulin secretion responsive to normal 
feedback controls (2). 
Pancreas transplantation was first described in 1967 
(2,3), but the initial pancreas graft and patient survival 
rates were dismal. A variety of factors, including 
advances in surgical techniques, immunosuppression, 
graft preservation techniques, methods of diagnosis and 
treatment of rejection, and management of common 
post-transplantation complications, have led to 
significant improvements in graft and patient survival. 
As a result, the total number of pancreas transplant 
procedures reported to the United Network of Organ 
Sharing and the International Pancreas Transplant 
Registry continued to increase - a total of 26,571 from 
December 1966 to October 2002, with most  
(n = 20,014) performed in the United States (3). 
 
Indications for and types of pancreas 
transplantation 
Patients with type 1 diabetes and end-stage renal 
disease (ESRD) have the choice of three transplant 
procedures- kidney transplant alone, simultaneous 
pancreas-kidney (SPK) transplant, or kidney transplant 
followed by pancreas transplant [pancreas after kidney 
(PAK) transplant], where the kidney graft is obtained 
from either a living or deceased donor. The usual 
indication for this procedure at most centers is a type 1 
diabetes patient with ESRD. 
SPK transplantation: In SPK transplantation, the 
pancreas and kidney are usually obtained from the 
same deceased donor. Therefore, changes in kidney 
function can be used to determine whether the rejection 
is occurring in either organ (4,5). 
PAK transplantation: This is the second most 
common pancreas transplant procedure. The indication 
for this procedure is a patient with type 1 diabetes who 
has identified a living donor for kidney transplant and 
wants to plan a later PAK transplant, or the type 1 
diabetes patient who already has a kidney transplant 
that has stable graft function, desires the potential 
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benefits of euglycemia, and has the cardiac reserve to 
undergo the procedure (4-7). 
Pancreas transplant alone (PTA): PTA is the least 
common pancreas transplant procedure performed. 
Frequent, severe, and hypoglycemic events are the 
most common indication for this procedure. The 
American Diabetes Association position statement 
suggests that indications for pancreas transplant (in the 
absence of kidney failure) are “frequent, acute and 
severe metabolic complications (hypoglycemia, 
hyperglycemia, and ketoacidosis) requiring medical 
attention” as well as “clinical and emotional problems 
with exogenous insulin therapy that are so severe as to 
be incapacitating; and consistent failure of insulin-
based management to prevent acute complications” (5). 
 
Surgical issues in pancreas transplantation 
Bladder versus enteric duct management: With 
bladder drainage (BD), urine amylase can be used as a 
marker of graft function. Biopsies of the pancreas graft 
are also easily obtained across the bladder wall through 
cystoscopy. However, this procedure also creates 
potential complications. Metabolic acidosis occurs in 
most cases, and extracellular volume depletion is 
common, occasionally severe enough to require 
hospitalization; both complications are due to the loss 
of sodium bicarbonate-rich pancreatic secretions into 
the urine. Additional problems that can complicate BD 
include bladder leak, reflux pancreatitis, particularly 
with neurogenic bladder, chemical cystitis/urethritis, 
and frequent bladder infections, duodenitis in the 
connecting segment, bladder tumors, bladder calculi, 
urethral stricture, urethral erosion, epididymitis, 
prostatitis, and prostatic abscess. The frequency of 
urological complications is high (50-77%), but they 
rarely result in graft or patient loss. 
The alternative to BD is enteric drainage (ED) of 
the exocrine duct. In this procedure, the pancreatic duct 
is inserted into the small bowel using a small “button” 
of duodenum or with a Roux-en-Y limb. There is less 
need for monitoring the pancreas graft, overall, because 
immunosuppression has improved and frequency of 
rejection episodes has decreased after pancreas 
transplant of all types. Indications for enteric 
conversion surgery (20–25%) are frequent episodes of 
severe extracellular volume depletion, severe metabolic 
acidosis, urological complications, or problems with 
the duodenal segment. 
SPK transplants performed with either BD or ED 
have equal pancreas graft survival (Figures 1 and 2). 
Portal versus systemic venous drainage (SVD): 
When placed in the systemic circulation - called SVD- 
the insulin secreted into the pancreatic venous effluent 
is not extracted immediately by the liver, as it would be 
if it emptied into the portal circulation. Systemic 
concentrations of insulin, both fasting and postprandial, 
are elevated as a result. Subsequently, a procedure was 
developed where the graft was placed in the portal 
circulation, and the pancreatic duct was drained into 
the small intestine.  
 
 
Figure 1. Unadjusted 1-, 3-, 5-, and 10-year patient survival after 
pancreas transplantation stratified by transplantation type 
Source 2008 OPTN/SRTR annual report. Table 1.13 
 
This combined portal venous drainage with ED 
procedure resulted in much lower peripheral insulin 
concentrations than pancreas transplant recipients with 
SVD, comparable to nondiabetic kidney transplants 
receiving similar immunosuppression. 
 
 
Figure 2. Unadjusted 1-, 3-, 5-, and 10-year graft survival 
(death is included as an event) after pancreas transplantation 
stratified by transplantation type 
Source 2008 OPTN/SRTR annual report. Table 1.13 
 
Complications 
The complexity of the whole pancreas transplant 
procedure, along with the likelihood of pre-existing 
disease secondary to their diabetes, exposes the 
recipient to a variety of significant operative and post-
operative risks. The extent of the post-operative 
problems likely limited the widespread acceptance of 
pancreas transplantation in the early era of its 
development. Serious surgical complications following 
the procedure include thrombosis of graft vessels, 
intra-abdominal hemorrhage, anastomotic leak (enteric 
or bladder), graft pancreatitis, pancreatic fistula 
formation, and intra-abdominal sepsis, all of which 
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may require re-laparotomy and the possibility of graft 
loss. In recent years, with improvements in donor and 
recipient selection criteria, surgical technique, 
immunosuppression protocols (reduced incidence of 
early and acute rejection), and prophylaxis regimes 
(antiviral, antibacterial, and antithrombosis), there has 
been a significant decrease in the overall incidence of 
serious complications and the rate of re-laparotomy. 
 
Immunosuppression 
The most common regimen in all pancreas transplant 
categories in 2000 was tacrolimus/mycophenolate 
mofetil (MMF, nearly 80%) with cyclosporine/MMF a 
distant second (5-20%) (6-8). The combination of 
tacrolimus/MMF has largely replaced 
cyclosporine/MMF because of some evidence of lower 
rejection rates, and better blood pressure and lipids. 
Other combinations are tacrolimus-sirolimus 
cyclosporine-sirolimus, tacrolimus-sirolimus-MMF, 
MMF-sirolimus, and sirolimus only. Many centers still 
use corticosteroids in their immunosuppression 
protocol, which may allow a reduced dose of 
calcineurin inhibitor, but others have tried to move to a 
“steroid-free” protocol with the assumption that this 
will decrease the risk of weight gain, glucose 
intolerance, dyslipidemia, and bone loss. The results of 
clinical pancreas transplantation continue to improve as 
immunosuppressive strategies become more targeted. 
Although corticosteroid withdrawal or avoidance is a 
clinical reality, particularly in SPK and PAK recipients, 
calcineurin inhibitor minimization, or elimination 
remains a work in progress. Induction 
immunosuppression is routinely used in whole pancreas 
transplantation, with >75% of recipients receiving either 
(1) a T-cell depleting polyclonal antibody 
(Thymoglobulin, ATGAM) or monoclonal antibody 
(OKT3, Campath); (2) a non-depleting monoclonal anti-
CD25 antibody (Zenapax, Simulect); or (3) both. 
The initial results with alemtuzumab induction 
appear quite promising, although it appears to be more 
effective when used as a conventional induction agent 
rather than a tolerance-inducing or maintenance 
immunosuppressant. In SPK recipients, both T-cell 
depleting and nondepleting antibody agents for 
induction have been used, whereas, in solitary PTX, the 
use of T-cell depleting antibodies has been greater. 
Monotherapy can be achieved in a proportion of patients, 
but it remains unclear which regimen is most effective and 
safe. Future clinical studies will continue to focus on long-
term outcomes, appropriate donor and recipient selection, 
immunologic monitoring, immunosuppressive reduction, 
and outcomes-based research. 
 
Results 
Whole-organ SPK transplant with normal graft 
function consistently improves 7- to 10-year patient 
survival compared with deceased donor kidney 
transplant, SPK transplant with loss of pancreas graft 
function, or dialysis in type1 diabetic patients waiting 
for a transplant (3). Patient survival after SPK 
transplant is consistently better than that observed after 
cadaveric donor kidney transplant, with the possible 
exception of recipients over age 50. Although this 
advantage may, in part, be due to improved glucose 
after SPK transplant compared with kidney transplant 
alone, differences between the recipients who undergo 
these procedures, and between the donor’s grafts used 
for these two procedures, would likely also contribute 
to the difference in survival described between these 
two procedures. Mortality after SPK transplant is equal 
to living donor kidney transplant alone after 10 years, 
and both PAK and PTA may increase 4-year mortality 
compared with remaining on the waiting list for those 
procedures. In these cases, specific quality of life 
concerns and impact of pancreas transplant on specific 
diabetic complications need to be weighed against 
potential early increase in mortality before these 
procedures are considered. Whole pancreas 
transplantation has proven to be a safe procedure with a 
1- and 3-year patient survival rates for all forms of 
pancreas transplant (SPK, PAK, and PTA) in the US 
since 1998 at almost 95%, and 89%, respectively 
(unadjusted patient survival rates, 2009 OPTN/SRTR 
Annual Report) (3-5). 
Serum glucose level normalizes immediately after 
pancreas transplant, at the expense of hyperinsulinemia 
if SVD is used. Insulin secretion demonstrates 
oscillations despite denervation, as well as normal first- 
and second-phase secretion responses unless there is a 
decrease in graft function or increased insulin 
resistance. C peptide concentrations are often slightly 
elevated, both basally and after mixed meal stimulus, 
but similar to those of non-diabetic kidney transplant 
recipients. Although fasting proinsulin is increased, it 
does not necessarily represent failing graft function, 
and glucagon response to hypoglycemia improves over 
time. Glucagon and symptom response to 
hypoglycemia return to normal or near normal over 
time; epinephrine and growth hormone responses 
though improve do not become normal after pancreas 
transplant. Hypoglycemic symptoms and documented 
events are uncommon and tend to diminish over time 
but may be due to a variety of factors. It should be 
cautioned that glucagon secretion in response to 
hypoglycemia does not improve with either allo- or 
auto-transplantation of islets into the liver, in human or 
animal studies, as described with pancreas transplant, 
and may be related to their location in the liver (8). 
Diabetic nephropathy can be prevented by a 
functioning pancreas graft, and pathological changes of 
diabetes can reverse over time after more than 5 years of 
normal pancreas function (9). Diabetic retinopathy may 
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worsen initially after pancreas transplantation with 
sudden improvement in glucose concentration; therefore, 
evaluation and treatment of pre-existing retinopathy are 
important when pancreas transplant surgery is being 
considered (9,10). After 3 or more years of pancreas 
graft function, less retinal surgery is required after SPK 
transplant compared with kidney transplant alone in 
patients who do not already have end-stage eye disease. 
Lifelong eye surveillance examinations are required in 
all pancreas transplant recipients as laser surgery may 
still be required, particularly early after transplant 
surgery. Furthermore, screening ophthalmic 
examinations are needed to evaluate cataracts that can 
form or progress, particularly in any patient treated with 
corticosteroids. Improvements in sensory and motor 
neuropathy occur after both SPK transplantation and 
kidney transplant alone. However, greater improvements 
have been reported after SPK transplant with ongoing 
improvements up to 10 years after the transplant. 
Autonomic neuropathies may take longer to improve (10 
years or more) and maybe only partially reversible or not 
reversible at all in some cases. Yet, some autonomic 
neuropathy parameters are improved in some studies, 
particularly hypoglycemia awareness, autonomic 
response to hypoglycemia, and cardiac autonomic 
neuropathies (11-14). 
The most common cause of death in diabetes and 
transplant patients is vascular disease. Improved 
glucose control, as with SPK transplant, can 
improve vascular reactivity and microvascular integrity 
and responses, but other factors after transplant may 
prevent or minimize these improvements in some 
patients (15-18). Changes in renal function; genetic 
predisposition to hypertension, dyslipidemia, or insulin 
resistance; the types of immunosuppressant used and 
their relative dose; changes in behavior as with weight 
gain or smoking cessation; and even donor and graft 
variables that contribute to delayed or decreased renal 
function, or frequency of rejection that increases the 
need for immune suppression may all impact risk over 
time (19). However, the results to date suggest that 
macro-vascular disease improves in most patients after 
SPK transplant, but inadequate data are available to 
comment on change in risk after PTA or PAK transplant. 
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